FDA Real-Time Clinical Trials
The FDA's move toward real-time clinical trials raises the bar for what a site has to prove. It does not retire the basics of site selection. It makes getting them right the first time non-negotiable.
Two proof-of-concept trials are live: AstraZeneca's TRAVERSE (Phase II, treatment-naive mantle cell lymphoma, sites including MD Anderson and the University of Pennsylvania) and Amgen's STREAM-SCLC (Phase Ib, limited-stage small cell lung carcinoma). Both report pre-agreed safety and efficacy signals as data emerges. The data does not move from the site straight to the agency. It passes through an intermediate platform, Paradigm Health in the current pilots, which validates the signal first.
In February 2026 the FDA made a single pivotal trial with confirmatory evidence the default for approval, ending the two-trial standard set in the 1960s. A sponsor now gets one chance to get the study right. A misjudged site no longer costs a few months of enrollment. It can cost the approval, and under RTCT the agency sees the damage while it is happening.
Signals recorded and transmitted as they occur, not batched for a monthly export.
EHR, EDC, and safety tools that talk to each other without manual reconciliation.
A delayed response now has a visible cost to the sponsor and the agency in near real time.
Adverse event review and escalation can no longer wait for a scheduled monitoring visit.
Coordinators need dedicated time for continuous review, not just visit-day documentation.
Faster reporting cannot come at the cost of accuracy, source verification, or patient privacy.
The single best predictor of whether a site can stream at all.
The sponsor needs the system's capabilities to judge compatibility with the study's EDC.
Ask for the commitment in writing and put the number in the contract.
Surfaces both the technical path and the site's comfort with using it.
Names the person who owns the cadence, before activation rather than after.
Almost no site has done this before. Willingness matters more than experience right now.
Partial participation would skew an analysis that runs continuously. Our reading, shared by several public comments, is that it has to be every site in a study. The FDA has not said so.
Whether a CRA and the sponsor verify and freeze a field before the interface pushes it to the agency is undefined. Nobody wants conclusions drawn from unreviewed data.
RBM already targets specific fields for near-real-time review. Whether RTCT absorbs it, runs alongside it, or replaces it is not settled.
There is no published mechanism for retracting or amending a signal the agency has already received. This is the question sponsors raise first.
Whether the site initiation visit still carries this, and who funds the added effort, is open. The training burden is real and it lands on the site.
Participants may need to be told that data about their response reaches the agency before the study ends. Expect consent language to catch up.
Define the screening or enrollment threshold, and the date it gets checked, in the contract. Not in the first steering committee after it is already late.
A site or network that can say "we thought we had these patients and we do not" early is worth more than one that waits. Transparency has to be safe, or it does not happen.
If a region has to contribute a set number of patients, the replacement site should be known before the original one stalls, not sourced afterward.
Geofenced referral outreach in a 10 to 50 mile radius around an otherwise strong site can restore supply without losing the investigator and the activation spend.
The takeaway
You still need investigators with real depth in the indication, a verifiable path to the right patients, and a research team that can execute. What is new is that a weak site is no longer a delay you absorb quietly. It is a risk to the program, visible to the agency while the study is still running, in a world where one pivotal trial carries the approval.
Get the Full Briefing
Take the four-page briefing to your team, or request a walkthrough of how we score sites on readiness rather than reputation.
Sources: FDA, "FDA Announces Major Steps to Implement Real-Time Clinical Trials" (Apr 28, 2026); FDA RFI comment-period extension, Federal Register (May 27, 2026); Makary and Prasad, New England Journal of Medicine, single-pivotal-trial default (Feb 2026); Commissioner Makary resignation reported May 12, 2026 (NBC, Washington Post, CBS, Time); FDA Chief AI Officer estimate of a 20 to 40% timeline reduction; ONC / HealthIT.gov, 2024 National Electronic Health Records Survey (N=1,725); KLAS 2026 EHR Market Share Report. Open questions and site-level practice reflect the discussion at LINEA Mastermind Session 9, July 23, 2026.